Tam Anh General Hospital named international research site for RBS2418

The initiative will include local biomarker testing.

Vietnam’s Tam Anh General Hospital has been designated as the first international research site for RBS2418, an oral immunotherapy drug developed to activate the immune system in combating cancer.

The hospital’s involvement forms part of the VISTA-1 clinical trial, a collaborative effort with US experts.

The initiative will include local biomarker testing, ensuring Vietnamese patients receive care and treatments comparable to international protocols.

The new drug targets terminal cancer patients, particularly those with advanced colorectal cancer who have not responded to existing treatments.